Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00691002
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190), LEO 80190 Vehicle, Hydrocortisone
- Where
- 11 sites in Croatia, Germany and 2 more
- Volunteers
- 1,245 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
- Trial name
- NCT02038569
- Testing
- LEO 80185 gel
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- LEO Pharma
Atopic Dermatitis (AD), Psoriasis
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function.
- Conditions
- Atopic Dermatitis (AD), Psoriasis, Acne Vulgaris, Contact Dermatitis
- Trial name
- NCT07066150
- Testing
- Apply a cream containing 0.05% marula oil-derived ceramide NPs
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shanghai Chicmax Cosmetic Co., Ltd.
Acne, Atopic Dermatitis
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected.
- Conditions
- Acne, Atopic Dermatitis, Psoriasis Vulgaris, Rosacea
- Trial name
- NCT04472546
- Testing
- in-vivo mesure, Scotch, Lipid index
- Where
- France
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study
This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia.
- Trial name
- BODYGUARD (NCT02636101)
- Testing
- Calcipotriol/betamethasone dipropionate gel
- Where
- Russia
- Volunteers
- 603 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%…
- Trial name
- NCT03731091
- Testing
- Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.)
- Where
- 30 sites in United States
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Psoriasis Vulgaris
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
- Trial name
- NCT02387853
- Testing
- LEO 90100
- Where
- 9 sites in United States, Netherlands and 2 more
- Volunteers
- 117 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, Psoriatic Arthritis
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system…
- Trial name
- NCT06191042
- Testing
- si-544
- Where
- 4 sites in Germany
- Volunteers
- 45 people
- Sponsor
- selectION Therapeutics GmbH
Psoriasis Vulgaris
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g)…
- Trial name
- NCT02533973
- Testing
- Xamiol® gel, Daivonex® scalp solution
- Where
- China
- Volunteers
- 951 people
- Sponsor
- LEO Pharma
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
- Trial name
- NCT01600222
- Testing
- LEO 90100
- Where
- 10 sites in Canada
- Volunteers
- 37 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
- Trial name
- NCT00287547
- Testing
- CTLA4Ig / Abatacept
- Where
- 10 sites in United States
- Volunteers
- 144 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
A Vasoconstriction Study With LEO 90100
The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with Dermovate® cream, Dovobet® ointment, betamethasone dipropionate in LEO90100 vehicle, Synalar® ointment and LEO 90100 vehicle using a human…
- Trial name
- NCT01946386
- Testing
- LEO 90100 Aerosol, foam, Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle, LEO 90100 Aerosol, foam, vehicle
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.
- Trial name
- NCT02796053
- Testing
- TAB08
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Theramab LLC
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg.
- Trial name
- ADJUST (NCT04306315)
- Testing
- Brodalumab
- Where
- 81 sites in Belgium, Czechia and 9 more
- Volunteers
- 385 people
- Sponsor
- LEO Pharma